ProQR Therapeutics
PRQR
32 hedge funds and large institutions have $97.1M invested in ProQR Therapeutics in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 9 closing their positions.
14% less funds holding
Funds holding: 37 → 32 (-5)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
40% less capital invested
Capital invested by funds: $162M → $97.1M (-$65.2M)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$4.95M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.73M |
| 3 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
+$1.15M |
| 4 |
Millennium Management
New York
|
+$842K |
| 5 |
Jennison Associates
New York
|
+$380K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$3.15M |
| 2 |
DM
Deerfield Management
New York
|
-$3.05M |
| 3 |
CCM
Century Capital Management
Boston,
Massachusetts
|
-$1.89M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$1.19M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$945K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
26
Sterling Capital Management
Charlotte,
North Carolina
| $92K | -$3.45K | -300 | -3% |
|
27
Wells Fargo
San Francisco,
California
| $30K | +$11K | +955 | +38% |
|
28
UBS Group
Zurich,
Switzerland
| $8K | -$2.83K | -246 | -20% |
|
|
HHMI
29
Howard Hughes Medical Institute
Chevy Chase,
Maryland
| $7K | -$483 | -42 | -5% |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | – | – | – |
|
31
Creative Planning
Overland Park,
Kansas
| $3K | – | – | – |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $1K | -$9.1K | -791 | -88% |
|
|
CCP
33
Clough Capital Partners
Boston,
Massachusetts
| – | -$3.15M | -216,200 | Closed |
|
|
DM
34
Deerfield Management
New York
| – | -$3.05M | -209,398 | Closed |
|
|
CCM
35
Century Capital Management
Boston,
Massachusetts
| – | -$1.89M | -129,408 | Closed |
|
|
36
Marshall Wace
London,
United Kingdom
| – | -$945K | -64,886 | Closed |
|
37
Morgan Stanley
New York
| – | -$488K | -33,516 | Closed |
|
38
Goldman Sachs
New York
| – | -$162K | -11,135 | Closed |
|
39
Walleye Trading
New York
| – | -$28K | -1,900 | Closed |
|
PRQR Hedge Fund Activity: Q4 2015 in Review
32 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2015, worth a combined $97.1M — down 40% from $162M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PRQR and 4 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was OrbiMed, adding an estimated $4.95M. The largest seller was Clough Capital Partners, exiting entirely with an estimated $3.15M sold.
- 32 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2015, down from 37 in Q3 2015.
- Funds reported $97.1M of ProQR Therapeutics stock for Q4 2015, down 40% quarter-over-quarter.
- 4 funds opened new ProQR Therapeutics positions in Q4 2015 and 9 closed out, a net change of -5 holders.
- The largest ProQR Therapeutics buyer in Q4 2015 was OrbiMed, an estimated $4.95M added.
- The largest ProQR Therapeutics seller in Q4 2015 was Clough Capital Partners, an estimated $3.15M sold.
Based on aggregated 13F filings for Q4 2015.